{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:51:03Z","timestamp":1788187863511,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The design focus of the first-generation COVID-19 vaccines was on the use of the SARS-CoV-2 spike (S) protein as the primary vaccine immunogen to induce high levels of neutralizing antibodies. Efficacy was repeatedly disrupted due to the diminished neutralizing capacity of vaccine-induced antibodies against emerging variants. Vaccine candidate GEO-CM04S1 is based on the use of a modified vaccinia Ankara vector (MVA) that co-expresses S and nucleocapsid (N) antigens of the Wuhan-Hu-1 reference strain. It is designed to induce both antibody and T-cell responses to both S and N, with the goal of broadening immune response specificity and function. Herein, we characterized GEO-CM04S1 vaccine induced immune responses and efficacy against the ancestral Wuhan strain B.1 and the Omicron subvariant XBB.1.5 in K18-hACE-2 mouse model. We also tested experimental vaccine candidates that encode either S or N proteins alone and determined their relative levels and immunogenicity and contribution to efficacy. We demonstrated that immune responses induced by GEO-CM04S1 protects against weight loss, upper and lower respiratory tract infection, lung injury and excessive inflammation following intranasal challenge with B.1. We showed that only GEO-CM04S1 maintained full protective efficacy against the Omicron subvariant XBB.1.5. GEO-CM04S1 vaccination reduced viral replication without significant lung damage following XBB.1.5 infection. Despite full protection, no neutralizing antibodies were detected against XBB.1.5 in the sera of GEO-CM04S1-immunized animals, suggesting a critical role of T-cell responses. Using antibody-mediated depletion, we showed that depletion of CD20 cells or CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells did not impact the vaccine protective efficacy whereas depletion of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cells diminished levels of efficacy. Collectively, our data demonstrate the full cross-variant protective immunity induced by GEO-CM04S1 and that CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell responses are a major effector element of vaccine protection.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1694699","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:26:03Z","timestamp":1762867563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants"],"prefix":"10.3389","volume":"16","author":[{"given":"Amany","family":"Elsharkawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchala","family":"Guglani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JD","family":"Burleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arban","family":"Domi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd R.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinonye","family":"Dim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa Rao","family":"Oruganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-coV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00911-y","article-title":"Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine","volume":"11","author":"Milane","year":"2021","journal-title":"Drug Delivery Trans Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v14061139","article-title":"Differential pathogenesis of SARS-coV-2 variants of concern in human ACE2-expressing mice","volume":"14","author":"Natekar","year":"2022","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/v14010027","article-title":"SARS-coV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice","volume":"14","author":"Stone","year":"2021","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100679","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02260-20","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus ankara expressing the SARS-coV-2 spike protein induce robust T- and B-cell immune responses and full efficacy in mice","volume":"95","author":"Garc\u00eda-Arriaza","year":"2021","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026785118","article-title":"One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11051006","article-title":"Vaccinia virus strain MVA expressing a prefusion-Stabilized SARS-CoV-2 spike glycoprotein induces robust protection and prevents brain infection in mouse and hamster models","volume":"11","author":"Lorenzo","year":"2023","journal-title":"Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"Chiuppesi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104745","article-title":"Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants","volume":"25","author":"Chiuppesi","year":"2022","journal-title":"IScience"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104457","article-title":"COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants","volume":"25","author":"Wussow","year":"2022","journal-title":"IScience"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00640-y","article-title":"Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants","volume":"8","author":"Wussow","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557535","article-title":"Virus-specific host responses and gene signatures following infection with major SARS-CoV-2 variants of concern: role of ZBP1 in viral clearance and lung inflammation","volume":"16","author":"Elsharkawy","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13070528","article-title":"Upregulation of neuroinflammation-associated genes in the brain of SARS-coV-2-infected mice","volume":"13","author":"Oh","year":"2024","journal-title":"Pathog (Basel Switzerland)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1466980","article-title":"Omicron XBB.1.5 subvariant causes severe pulmonary disease in K18-hACE-2 mice","volume":"15","author":"Elsharkawy","year":"2024","journal-title":"Front Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1275823","article-title":"The critical role of interleukin-6 in protection against neurotropic flavivirus infection","volume":"13","author":"Auroni","year":"2023","journal-title":"Front Cell Infection Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040362","article-title":"Multivalent and sequential heterologous spike protein vaccinations effectively induce protective humoral immunity against SARS-coV-2 variants","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1621226","article-title":"SARS-CoV-2 XBB.1.5 infects wild-type C57BL\/6 mice and induces a protective CD4+ T cell response required for viral clearance","volume":"15","author":"Elsharkawy","year":"2025","journal-title":"Front Cell Infection Microbiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12915-025-02293-w","article-title":"Development and characterization of a fully humanized ACE2 mouse model","volume":"23","author":"Ge","year":"2025","journal-title":"BMC Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01726-6","article-title":"mRNA-encoded Cas13 can be used to treat dengue infections in mice","volume":"9","author":"Basu","year":"2024","journal-title":"Nat Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5c00153","article-title":"Multilayer fluorescent immunoassay for early and sensitive dengue virus detection using host and viral biomarkers","author":"Browne","year":"2025","journal-title":"Bioconjugate Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040411","article-title":"Multi-antigen viral-vectored vaccine protects against SARS-coV-2 and variants in a lethal hACE2 transgenic mouse model","volume":"13","author":"Stone","year":"2025","journal-title":"Vaccines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells","volume":"8","author":"Ferrari de Andrade","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155789","article-title":"A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies","volume":"9","author":"Shi","year":"2024","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500615","article-title":"MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity","volume":"15","author":"Grewe","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2387906","article-title":"Heterologous mRNA\/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium","volume":"13","author":"Marcos-Villar","year":"2024","journal-title":"Emerging Microbes Infections"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1420304","article-title":"MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses","volume":"15","author":"P\u00e9rez","year":"2024","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00521-24","article-title":"Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice","volume":"98","author":"Zhu","year":"2024","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.028","article-title":"High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR","volume":"135","author":"Assaad","year":"2020","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0263328","DOI":"10.1371\/journal.pone.0263328","article-title":"Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients","volume":"17","author":"Bassi","year":"2022","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1038\/s41467-022-34657-z","article-title":"Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological Malignancies","volume":"13","author":"Cook","year":"2022","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.15585\/mmwr.mm7128a3","article-title":"Safety monitoring of COVID-19 mRNA vaccine first booster doses among persons aged \u226512 years with presumed immunocompromise status - United States, January 12, 2022-march 28, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR. Morbidity Mortality Weekly Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006627","article-title":"Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study","volume":"6","author":"Haydu","year":"2022","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12920","article-title":"Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City","volume":"22","author":"Miyashita","year":"2021","journal-title":"HIV Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13827","article-title":"Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection","volume":"24","author":"Morris","year":"2022","journal-title":"Transplant Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12020244","article-title":"SARS-coV-2-specific T cell responses in immunocompromised individuals with cancer, HIV or solid organ transplants","volume":"12","author":"Reeg","year":"2023","journal-title":"Pathogens"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0104-9","article-title":"SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer","volume":"1","author":"Rugge","year":"2020","journal-title":"Nat Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"Lancet Microbe"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00902-8","article-title":"Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection","volume":"22","author":"Zuo","year":"2021","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1694699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:26:03Z","timestamp":1762867563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1694699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2025.1694699"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1694699","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1694699"}}